Market revenue in 2023 | USD 8,428.2 million |
Market revenue in 2030 | USD 13,491.0 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
Fastest growing segment | Antibody Drug Conjugate (ADC |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.92% in 2023. Horizon Databook has segmented the Latin America active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
Latin America’s proximity to North America can help it reduce supply chain concerns, boosting its market. Presence of supportive regulatory frameworks and increase in foreign collaborations are anticipated to further drive the market.
The region is expected to show lucrative growth owing to the cost-effective solutions offered by its CDMOs and an increase in the number of new regional players venturing into the pharmaceutical & biotechnology markets. An increase in number of contract research and manufacturing organizations venturing into this region is anticipated to further drive the market over the forecast period.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account